FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor–expressing metastatic colorectal cancer patients treated …
WU Zhang, M Gordon, AM Schultheis… - Journal of clinical …, 2007 - ascopubs.org
Purpose Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti–epidermal growth factor
receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with …
receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with …
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
B Jacobs, W De Roock, H Piessevaux… - Journal of clinical …, 2009 - ascopubs.org
Purpose To study the power of the epidermal growth factor receptor (EGFR) epiregulin
(EREG) and amphiregulin (AREG) ligands' expression in primary tumors to predict the …
(EREG) and amphiregulin (AREG) ligands' expression in primary tumors to predict the …
Metastatic colorectal cancer: from improved survival to potential cure
DJ Gallagher, N Kemeny - Oncology, 2010 - karger.com
Context: The treatment of colorectal cancer has improved considerably in recent years, but it
remains the second commonest cause of cancer deaths in men and women in the United …
remains the second commonest cause of cancer deaths in men and women in the United …
Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
V Heinemann, S Stintzing, T Kirchner, S Boeck… - Cancer treatment …, 2009 - Elsevier
The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and
tumor progression of colorectal cancer (CRC). As a result, the EGFR has evolved as a …
tumor progression of colorectal cancer (CRC). As a result, the EGFR has evolved as a …
EGFR targeting of solid tumors
CM Rocha-Lima, HP Soares, LE Raez… - Cancer …, 2007 - journals.sagepub.com
Background Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-
targeted agents could benefit many patients with cancer. Methods We review the current …
targeted agents could benefit many patients with cancer. Methods We review the current …
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non–small-cell …
S Khambata-Ford, CT Harbison, LL Hart… - Journal of clinical …, 2010 - ascopubs.org
Purpose The anti–epidermal growth factor receptor (EGFR) antibody cetuximab is
efficacious in multiple tumor types. Patient selection with markers predictive of benefit may …
efficacious in multiple tumor types. Patient selection with markers predictive of benefit may …
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
H Prenen, J De Schutter, B Jacobs, W De Roock… - Clinical cancer …, 2009 - AACR
Purpose: It has been reported that activating KRAS mutations negatively affect response to
anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic …
anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic …
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
A Jakobovits, RG Amado, X Yang, L Roskos… - Nature …, 2007 - nature.com
Therapeutic monoclonal antibodies have shown limited efficacy and safety owing to
immunogenicity of mouse sequences in humans. Among the approaches developed to …
immunogenicity of mouse sequences in humans. Among the approaches developed to …
[HTML][HTML] Downregulation of AC092894. 1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis
Z Zheng, M Wu, H Li, W Xu, M Yang, K Pan, Y Ni… - BMC medicine, 2023 - Springer
Background Oxaliplatin resistance is a complex process and has been one of the most
disadvantageous factors and indeed a confrontation in the procedure of colorectal cancer …
disadvantageous factors and indeed a confrontation in the procedure of colorectal cancer …
[HTML][HTML] Lnc-RP11-536 K7. 3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids
Q Li, H Sun, D Luo, L Gan, S Mo, W Dai, L Liang… - Journal of Experimental …, 2021 - Springer
Background Resistance to oxaliplatin is a major obstacle for the management of locally
advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) …
advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) …